نتایج جستجو برای: nonsmall cell lung cancer nsclc

تعداد نتایج: 2482650  

Journal: :The European respiratory journal 2007
J P Sculier J J Lafitte M Paesmans J Lecomte C G Alexopoulos O Van Cutsem V Giner A Efremidis M C Berchier T Collon A P Meert A Scherpereel V Ninane G Koumakis M M Vaslamatzis N Leclercq T Berghmans

The aim of the present study was to determine the potential benefit of conventional cisplatin-based chemotherapy on patients with advanced nonsmall cell lung cancer (NSCLC) and poor performance status (PS), defined as 60-70 on the Karnofsky scale. Retrospective analysis was carried out of a randomised trial performed in advanced NSCLC where 485 patients received three courses of gemcitabine+ifo...

Journal: :Current opinion in oncology 2002
George Dranitsaris Wayne Cottrell William K Evans

After decades of research into its prevention and treatment, lung cancer remains the leading cause of cancer death in North America and Europe. Approximately 75% of all new lung cancer diagnoses are of the nonsmall-cell subtype, and less than 25% of these patients are potentially operable upon first detection. First-generation cisplatin-based chemotherapy regimens for patients with metastatic d...

Journal: :The European respiratory journal 2017
Jules L Derks Robert Jan van Suylen Erik Thunnissen Michael A den Bakker Harry J Groen Egbert F Smit Ronald A Damhuis Esther C van den Broek Ernst-Jan M Speel Anne-Marie C Dingemans

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is rare. Chemotherapy for metastatic LCNEC ranges from small cell lung carcinoma (SCLC) regimens to nonsmall cell lung carcinoma (NSCLC) chemotherapy regimens. We analysed outcomes of chemotherapy treatments for LCNEC.The Netherlands Cancer Registry and Netherlands Pathology Registry (PALGA) were searched for patients with stage IV chemother...

Journal: :PLOS Biology 2021

Tumor heterogeneity is a primary cause of treatment failure and acquired resistance in cancer patients. Even cancers driven by single mutated oncogene, variability response to targeted therapies well known. The existence additional genomic alterations among tumor cells can only partially explain this variability. As such, nongenetic factors are increasingly seen as critical contributors relapse...

J. Li, K. Liao, S.L. Wu, X.Y. Li,

Background: Radiotherapy is the gold standard in the treatment of lung cancer. However, the radiosensitization of cancerous cells requires further improvement. Here, we investigated the effect of dihydroartemisinin (DHA) on the radiosensitization of non-small cell lung cancer (NSCLC) cells. Methods: Cell proliferation and cell cycle assays were carried out using A549 cells exposed to DHA. The e...

Journal: :Annals of palliative medicine 2021

Background: Skeletal muscle radiodensity is associated with postoperative complications in cancer. However, data on skeletal and complication risk patients non-small cell lung cancer (NSCLC) are scarce, this study investigated the relationship between NSCLC treated by thoracoscopic lobectomy.

Journal: :The European respiratory journal 2006
S Rossi R Dore A Cascina V Vespro F Garbagnati L Rosa V Ravetta A Azzaretti P Di Tolla G Orlandoni E Pozzi

The aim of the current study was to evaluate the safety and the efficacy of radiofrequency thermal ablation (RFTA) for the treatment of nonsmall cell lung cancer (NSCLC) and isolated pulmonary metastases (METs) from colorectal cancer (CRC). A total of 31 patients (15 with NSCLCs and 16 with CRC lung METs), with 36 lung tumour nodules (mean+/-sd diameter: 22+/-8 mm, range: 10-35 mm) underwent co...

2016
J. ZHANG Y.-X. WANG

4494 Abstract. – OBJECTIVE: This study is aimed to investigate the cellular role of miR-377 and demonstrate that miR-377 negatively regulated cyclin-dependent kinase 6(CDK6) in human nonsmall cell lung cancer (NSCLC) cells. MATERIALS AND METHODS: qRT-PCR was performed to identify the miR-377 expression level in 45 paired NSCLC and adjacent normal lung tissues. Cell proliferation was measured by...

Journal: :International Journal of Cancer 2021

The gastrointestinal microbiota was reported as an important factor for the response to cancer immunotherapy. Probiotics associated with dysbiosis and bacterial richness may affect efficacy of immunotherapy drugs. However, clinical impact probiotics on in patients nonsmall cell lung (NSCLC) is poorly understood. outcomes 294 advanced or recurrent NSCLC who received antiprogrammed death-1 (PD-1)...

Journal: :European Respiratory Review 2013

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید